Tag Archives: Clinical

Beta-Blockers Post MI: A Clear Clinical Message  Medscape Doctors may need to rethink decades of routine beta blocker use for some patients after a heart attack, studies suggest  ABC News Does a common heart attack pill help everyone? Studies disagree  Reuters Beta-blockers have detrimental impact on health of women users – study  The Independent Common heart drug taken by millions found useless, possibly risky  ScienceDaily …

U.S. pharmaceutical giant Eli Lilly (LLY) says it is preparing for the approval and launch of its new weight loss pill following the results of a late-stage clinical trial. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The Indianapolis, Indiana-based …

Immunotherapy vaccine attacks cancer cells A virus that infects the humble black-eyed pea plant is showing great promise as a low-cost, potent cancer immunotherapy—thanks to researchers at the University of California San Diego. The team led by chemical and nano engineers just published their study in Cell Biomaterials, showing how the cowpea mosaic virus (CPMV), unlike other plant viruses, is …

A team at the University of Virginia has developed a monoclonal antibody to stop sepsis, the leading cause of death in U.S. hospitals. There is good news from Virginia when it comes to the deadly infection sepsis. “This is truly a groundbreaking discovery,” said Jianjie Ma, a professor in the department of surgery at the University of Virginia. “Sepsis is …

Histology image of a patient whose metastatic cancer went into complete remission after receiving a new immunotherapy treatment (Ravetch lab) Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment. While effective at activating the immune system to kill cancer cells in animal models, the drugs had limited impact …

Notoriously hard to treat, pancreatic and colorectal cancers each have high recurrence rates in the years following treatment. A new ‘off-the-shelf’ vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly diseases following promising outcomes in a recent clinical trial. Developed by researchers from institutions across the US, the vaccine targets mutations in the …

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease1  Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren’s …

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back. Pancreatic cancer is of particular concern. The five-year survival rate is about 13%, and up to 80% of pancreatic cancers may come back. “If you were to ask me what disease most needs something to prevent recurrences, I’d say this one,” said Dr. …

When her balance issues first started, Mary Pat Mirus thought she was just getting old. She struggled to pick up her feet, gripped walls for support and wobbled when she walked her dog, a Mi-Ki named Betty White. After years of doctors’ visits with clean scans and no diagnosis, Mirus, 72, resigned herself to never figuring her condition out. “Everything …

Pioneering an AI clinical copilot with Penda Health  OpenAI Source link